FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146838679> ?p ?o ?g. }

• W2146838679 endingPage "1282" @default.
• W2146838679 startingPage "1275" @default.
• W2146838679 abstract "Abstract Doxorubicin is an effective anticancer agent that is limited by numerous adverse effects, cardiotoxicity causing the most concern. Its alcohol metabolite, doxorubicinol, and free radicals have been implicated in the aetiology of this toxicity. This study was based on the premise that inhibition of aldo-keto reductases would improve the efficacy of doxorubicin by reducing its toxic metabolites and modifying its pharmacokinetics. We assessed the effect of in-vitro inhibition of aldo-keto reductases on the metabolism of doxorubicin in cytosolic fractions of heart and liver of rats in the presence of Na-phenobarbital. The inhibition was confirmed by a significant reduction in the formation of doxorubicinol. The results of the in-vitro study were further evaluated in-vivo. The concentrations of doxorubicin in plasma, bile and urine and its major metabolites in bile and urine were measured in Na-phenobarbital-pretreated rats. Each rat received 100 mg kg−1/day intraperitoneal injection of sodium phenobarbital for three days followed by a single intravenous dose of 10 mg kg−1 [14C-14]doxorubicin (sp. act. 0.2 μCi mg−1) on the fourth day. The levels of drug in all biological samples were measured by HPLC. The pretreatment resulted in an increase in biological half-life (5.8 ± 1.5 vs 3.7 ± 0.93 h control group, P &lt; 0.05) and area under plasma concentration-time curve (19.6 ± 1.7 vs 14.65 ± 1.68 mg h L−1 control group, P &lt; 0.05). The cumulative amount of doxorubicinol in the bile and urine of pretreated animals was reduced significantly. In terms of % dose, the amount in the bile declined from 4.2 ± 0.8% in control to 2.4 ± 0.3% and in urine from 0.18 ± 0.08% to 0.12 ± 0.07%. There were no significant changes in doxorubicin aglycone and doxorubicinol aglycone. Serum creatine kinase levels were measured as a biomarker of damage to cardiac muscle. The area under creatine kinase level-time curve was reduced by approximately 50% in phenobarbital-pretreated animals. The results indicate that the inhibition of aldo-keto reductase could provide a useful approach to improve the safety of doxorubicin by reducing its alcohol metabolite. Furthermore, if the reduction in the area under the serum creatine kinase-time curve represents a reduced damage to heart muscle, it can be concluded that doxorubicinol plays an important role in this injury." @default.
• W2146838679 created "2016-06-24" @default.
• W2146838679 creator A5003036568 @default.
• W2146838679 creator A5046815152 @default.
• W2146838679 date "1999-11-01" @default.
• W2146838679 modified "2023-10-14" @default.
• W2146838679 title "Inhibition of Aldo-keto Reductases by Phenobarbital Alters Metabolism, Pharmacokinetics and Toxicity of Doxorubicin in Rats" @default.
• W2146838679 cites W131965410 @default.
• W2146838679 cites W1588145468 @default.
• W2146838679 cites W1971789415 @default.
• W2146838679 cites W1982789243 @default.
• W2146838679 cites W1986674874 @default.
• W2146838679 cites W2001071975 @default.
• W2146838679 cites W2002967757 @default.
• W2146838679 cites W2018665136 @default.
• W2146838679 cites W2029769919 @default.
• W2146838679 cites W2034113803 @default.
• W2146838679 cites W2049755195 @default.
• W2146838679 cites W2055225624 @default.
• W2146838679 cites W2070147796 @default.
• W2146838679 cites W2071657527 @default.
• W2146838679 cites W2072336242 @default.
• W2146838679 cites W2076967735 @default.
• W2146838679 cites W2111426313 @default.
• W2146838679 cites W2132777822 @default.
• W2146838679 cites W24116936 @default.
• W2146838679 cites W2138862007 @default.
• W2146838679 doi "https://doi.org/10.1211/0022357991777010" @default.
• W2146838679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10632085" @default.
• W2146838679 hasPublicationYear "1999" @default.
• W2146838679 type Work @default.
• W2146838679 sameAs 2146838679 @default.
• W2146838679 citedByCount "42" @default.
• W2146838679 countsByYear W21468386792013 @default.
• W2146838679 countsByYear W21468386792014 @default.
• W2146838679 countsByYear W21468386792017 @default.
• W2146838679 countsByYear W21468386792021 @default.
• W2146838679 countsByYear W21468386792022 @default.
• W2146838679 crossrefType "journal-article" @default.
• W2146838679 hasAuthorship W2146838679A5003036568 @default.
• W2146838679 hasAuthorship W2146838679A5046815152 @default.
• W2146838679 hasBestOaLocation W21468386791 @default.
• W2146838679 hasConcept C112705442 @default.
• W2146838679 hasConcept C121608353 @default.
• W2146838679 hasConcept C126322002 @default.
• W2146838679 hasConcept C150903083 @default.
• W2146838679 hasConcept C178790620 @default.
• W2146838679 hasConcept C185592680 @default.
• W2146838679 hasConcept C202751555 @default.
• W2146838679 hasConcept C207001950 @default.
• W2146838679 hasConcept C2776694085 @default.
• W2146838679 hasConcept C2776802502 @default.
• W2146838679 hasConcept C2777477808 @default.
• W2146838679 hasConcept C2778793413 @default.
• W2146838679 hasConcept C2781303535 @default.
• W2146838679 hasConcept C29730261 @default.
• W2146838679 hasConcept C530470458 @default.
• W2146838679 hasConcept C55493867 @default.
• W2146838679 hasConcept C62231903 @default.
• W2146838679 hasConcept C71924100 @default.
• W2146838679 hasConcept C86803240 @default.
• W2146838679 hasConcept C87644729 @default.
• W2146838679 hasConcept C98274493 @default.
• W2146838679 hasConceptScore W2146838679C112705442 @default.
• W2146838679 hasConceptScore W2146838679C121608353 @default.
• W2146838679 hasConceptScore W2146838679C126322002 @default.
• W2146838679 hasConceptScore W2146838679C150903083 @default.
• W2146838679 hasConceptScore W2146838679C178790620 @default.
• W2146838679 hasConceptScore W2146838679C185592680 @default.
• W2146838679 hasConceptScore W2146838679C202751555 @default.
• W2146838679 hasConceptScore W2146838679C207001950 @default.
• W2146838679 hasConceptScore W2146838679C2776694085 @default.
• W2146838679 hasConceptScore W2146838679C2776802502 @default.
• W2146838679 hasConceptScore W2146838679C2777477808 @default.
• W2146838679 hasConceptScore W2146838679C2778793413 @default.
• W2146838679 hasConceptScore W2146838679C2781303535 @default.
• W2146838679 hasConceptScore W2146838679C29730261 @default.
• W2146838679 hasConceptScore W2146838679C530470458 @default.
• W2146838679 hasConceptScore W2146838679C55493867 @default.
• W2146838679 hasConceptScore W2146838679C62231903 @default.
• W2146838679 hasConceptScore W2146838679C71924100 @default.
• W2146838679 hasConceptScore W2146838679C86803240 @default.
• W2146838679 hasConceptScore W2146838679C87644729 @default.
• W2146838679 hasConceptScore W2146838679C98274493 @default.
• W2146838679 hasIssue "11" @default.
• W2146838679 hasLocation W21468386791 @default.
• W2146838679 hasLocation W21468386792 @default.
• W2146838679 hasOpenAccess W2146838679 @default.
• W2146838679 hasPrimaryLocation W21468386791 @default.
• W2146838679 hasRelatedWork W1884012693 @default.
• W2146838679 hasRelatedWork W1974165727 @default.
• W2146838679 hasRelatedWork W1978748450 @default.
• W2146838679 hasRelatedWork W1985176156 @default.
• W2146838679 hasRelatedWork W2073719851 @default.
• W2146838679 hasRelatedWork W2090709712 @default.
• W2146838679 hasRelatedWork W2103681475 @default.
• W2146838679 hasRelatedWork W2395431819 @default.
• W2146838679 hasRelatedWork W2410964138 @default.

• next